Sir,

We read with interest the report, recently published by Nahar *et al*.\[[@ref1]\] on the prevalence of warfarin sensitive alleles in factor V Leiden (FVL) mutation carriers. The study provides preliminary evidence for the need of pre-prescription genotyping of warfarin sensitive polymorphisms (CYP2C9\*2, \*3 and Vitamin-K epoxide reductase complex subunit1 \[VKORC1\]-1639G/A) in patients who are at risk of thrombosis (carriers of thrombophilic marker) and require anticoagulation therapy.

The authors have reported that 55.6% of the patients who carry FVL mutation also carry warfarin sensitive genotypes; thus, it is important that all patients with thrombophilia need warfarin genotyping prior to prescription with warfarin. The prevalence of these genotypes are however, not significantly different in few other studies including ours \[[Table 1](#T1){ref-type="table"}\], where the allele frequencies were studied in warfarin anticoagulated patients, as well as normal healthy controls.\[[@ref2][@ref3]\] FVL mutation has however, not been studied in these cases.

###### 

Genotype and allele frequencies of CYP2C9 and VKORC1 in few studies from India

![](IJHG-19-377-g001)

In our study, which included 145 warfarin treated patients (blinded to FVL or other thrombophilic marker carrier status), nearly 44.14% patients were found to be carriers for one or more variant genotype(CYP2C9\*2, \*3 and VKORC1-1639G/A). Out of these warfarin sensitive genotype carrier patients, 67.18% patients faced over anticoagulation (INR \> 4) while on warfarin. Indicating that genotyping of warfarin sensitive markers will be beneficial in all the patients prior to the initiation of anticoagulation therapy.\[[@ref3]\]

Another important aspect of coinheritance of thrombophilia is its impact on the bleeding phenotype. Several studies, both *in vitro* and case series have shown that FVL mutation modulates the clinical severity in hemophilia and other rare bleeding disorders.\[[@ref4][@ref5]\] We therefore premise that FVL carrier patients should be at lower risk of over anticoagulation than the FVL non-carrier patients. This would be confirmed by undertaking studies in large series of anticoagulated patients with the long duration follow-up analysis for over anticoagulation and risk of bleeding in carriers of thrombophilia marker versus non-carriers.
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